CD274 and triple-negative breast carcinoma: Thus, the association of anti-PD-(L)1 monoclonal antibody with taxanes-based chemotherapy was approved for the first-line treatment of unresectable triple-negative breast cancer or metastatic squamous NSCLC (33–35).